Osimertinib has become the reference treatment for EGFR-mutated non-small cell lung cancer (NSCLC), and hospital pharmacies, oncology centres and chemists across India now field the same questions again and again: which osimertinib 80 mg brands are in the market, how do they differ, and how can a buyer confirm that stock is genuine and correctly handled? This guide answers those questions from a distributor’s point of view. It is written for procurement teams, hospital pharmacists and oncology clinics, not for patients, and it does not replace the prescribing information or an oncologist’s judgement.
What Is Osimertinib?
Osimertinib is an oral, third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI). It targets the common sensitising EGFR mutations (exon 19 deletions and exon 21 L858R) as well as the T790M resistance mutation, and it penetrates the central nervous system, which matters in a disease where brain metastases are common. It is supplied as 40 mg and 80 mg tablets, and the usual labelled dose is 80 mg once daily. Its originator brand is Tagrisso, developed by AstraZeneca.
EGFR mutations are found in a considerably larger share of NSCLC patients in Asia than in Western populations, which is one reason osimertinib demand in India has grown steadily. Confirmation of the mutation by a validated test is a prerequisite for therapy, so osimertinib is only ever dispensed against a specialist prescription.
Where Osimertinib Is Used: Indications in Brief
According to the manufacturer’s labelling, osimertinib is approved for first-line treatment of locally advanced or metastatic EGFR-mutated NSCLC, for T790M-positive disease after progression on an earlier EGFR TKI, as adjuvant therapy after tumour resection in early-stage EGFR-mutated NSCLC, and for locally advanced unresectable disease following platinum-based chemoradiation. In first-line advanced disease it is also used in combination with pemetrexed and platinum chemotherapy. Exact approved indications differ between countries, so hospital teams should always check the label that applies to the product they are buying.
The Evidence Behind Osimertinib
In the FLAURA trial, first-line osimertinib was compared with the older EGFR TKIs gefitinib or erlotinib and extended median progression-free survival to 18.9 months versus 10.2 months. Later analyses also showed an overall survival advantage. The FLAURA2 trial then tested osimertinib with and without pemetrexed plus platinum chemotherapy; in the final overall survival analysis, median overall survival was 47.5 months with the combination versus 37.6 months with osimertinib alone (hazard ratio 0.77). Further trials such as ADAURA (adjuvant) and LAURA (unresectable stage III after chemoradiation) support its use earlier in the disease course. For the full data, readers should refer to the original publications and the prescribing information.
Osimertinib 80 mg Brands in India: What Buyers Should Know
Search results and online trade listings in India show osimertinib 80 mg under several names. Tagrisso is the originator brand. Other names that appear in listings and in buyer enquiries include Osicent, Osimert and Tagrix. Availability, labelling, import authorisation and patent status of these products are not uniform, and a brand name appearing on a trade portal is not proof that a product is genuine or lawfully supplied in India. A.K. Pharma does not make comparative claims between brands; the points below are the checks a careful buyer should run before purchasing any osimertinib 80 mg stock.
| Check | What to confirm |
|---|---|
| Product identity | Generic name (osimertinib), strength (40 mg or 80 mg), tablet count per pack and manufacturer name on the carton and strip |
| Supplier licence | Valid drug licence of the distributor and invoice in the institution’s name |
| Source | Whether the product comes through the manufacturer’s authorised channel or a legally permitted import route |
| Batch documents | Batch number, manufacturing and expiry dates, and certificate of analysis where available |
| Storage and transit | Storage within the labelled temperature range and intact packaging on arrival |
| Regulatory status | Whether the specific brand is approved or permitted for sale in India for the intended use |
Osimertinib Price in India: Why There Is No Single Figure
Buyers frequently search for “osimertinib price in India” or “osimertinib 80 mg price”, but a single quoted figure is rarely reliable. The landed cost of an imported or specialty oncology tablet depends on the brand and source, pack size, current batch availability, taxes, and any patient assistance or access programme in force. Because these factors change, prices are confirmed by quotation at the time of order rather than published on a blog. Institutions comparing quotes should compare like for like: same strength, same pack size, same batch documentation and same delivery terms.
Procurement Checklist for Hospitals and Pharmacies
Oncology tablets carry high value per pack, which makes them a target for counterfeiting and diversion. A sound procurement process for osimertinib 80 mg should include verifying the supplier’s licence, buying only against a valid prescription or institutional indent, inspecting packaging and batch details on receipt, recording batch numbers for traceability, and escalating any mismatch immediately. Our related guide, How to Verify Imported Cancer Medicines Are Genuine, walks through these checks in detail, and How A.K. Pharma Ensures Genuine Medicine Supply Across India describes our own process.
Related Reading
Lung cancer centres often source several linked medicines together. Other pages that may help include the older EGFR TKI Zefotib (gefitinib), the PD-L1 inhibitor Imfinzi (durvalumab) with Imjudo (tremelimumab), and our guide Imfinzi (Durvalumab) in India 2026. For antibody-drug conjugates see Enhertu and the ADC Revolution. The complete range is listed under Cancer Medicines and on our Products page, and details of free support are on the Patient Assistance Program page.
Sources
Soria JC et al., osimertinib in untreated EGFR-mutated advanced NSCLC (FLAURA), New England Journal of Medicine. Planchard D et al., survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC (FLAURA2), PubMed 41104938. Manufacturer prescribing information for osimertinib tablets.
Bulk Enquiries for Osimertinib 80 mg
A.K. Pharma is a licensed medicine distributor in Delhi supplying specialty and imported oncology medicines to hospitals, oncology centres and pharmacies across India. For availability, documentation and quotations on Tagrisso (osimertinib), call 011 4172 6999 or WhatsApp +91 9810034827, or reach us through the About Us page for our contact details.
What brands of osimertinib 80 mg are listed in India?
Tagrisso is the originator brand. Names such as Osicent, Osimert and Tagrix also appear in trade listings and buyer enquiries, but approval, import authorisation and availability vary, so buyers should verify the source and documentation of any brand before purchasing.
What is the price of osimertinib 80 mg in India?
There is no single fixed price. It depends on brand, source, pack size, batch availability and taxes, so it is confirmed by quotation at the time of order.
What is osimertinib used for?
Osimertinib is used for EGFR-mutated non-small cell lung cancer, including first-line advanced disease, T790M-positive disease, adjuvant therapy after resection and unresectable stage III disease after chemoradiation, as described in the manufacturer’s labelling. It is prescribed only after mutation testing.
How can a hospital check that osimertinib stock is genuine?
Verify the distributor’s drug licence, buy through an authorised or legally permitted channel, inspect the carton and strip, record batch and expiry details, and request batch documentation. Any mismatch should be escalated before the stock is used.
Does A.K. Pharma supply osimertinib in bulk?
A.K. Pharma supplies specialty oncology medicines, including Tagrisso (osimertinib), to hospitals, oncology centres and pharmacies. Contact 011 4172 6999 or WhatsApp +91 9810034827 for availability and a quotation.
Disclaimer: This article is for informational and B2B procurement purposes only and is not medical advice. A.K. Pharma is a distributor, not a prescriber or manufacturer. Treatment decisions must be made by a qualified oncologist, and prescribing information should be consulted for approved uses, dosing and safety.
